BCDA BioCardia, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 925741 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY-100.0%
TTM net income YoY-3.5%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-950.1%
ROA-230.6%
ROIC (approx.)—
Asset turnover0.00x
Leverage & solvency
Liabilities / assets73.8%
Debt / equity0.00x
Current ratio1.12x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.90x
Accruals ratio-22.2%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | $0 | $0 | $0 | $0 | $0 |
| R&D expense | $1.24M | $893,000 | $1.24M | $1.13M | $936,000 | $1.37M | $1.53M | $1.42M |
| SG&A expense | $600,000 | $730,000 | $1.03M | $885,000 | $552,000 | $683,000 | $1.20M | $906,000 |
| Operating income | -$1.83M | -$1.62M | -$2.27M | -$2.01M | -$1.49M | -$2.05M | -$2.73M | -$2.32M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$1.82M | -$1.61M | -$2.26M | -$1.98M | -$1.48M | -$2.05M | -$2.71M | -$2.30M |
| EBITDA | -$1.83M | -$1.62M | -$2.26M | -$2.01M | -$1.48M | -$2.05M | -$2.71M | -$2.31M |
| EPS (basic) | -0.12 | -0.13 | -0.21 | — | -0.24 | -0.40 | -0.59 | — |
| EPS (diluted) | — | — | -0.21 | — | -0.24 | -0.40 | -0.59 | — |
| Weighted avg. shares (diluted) | — | — | 10.81M | — | 6.28M | 5.06M | 4.64M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $2.22M | $4.12M | $951,000 | $2.50M | $5.29M | $980,000 | $949,000 | $2.37M |
| Receivables | $30,000 | $30,000 | $20,000 | $20,000 | — | $10,000 | — | $0 |
| Current assets | $2.33M | $4.30M | $1.14M | $2.73M | $5.37M | $1.20M | $1.17M | $2.62M |
| PP&E, net | $12,000 | $13,000 | $16,000 | $16,000 | $13,000 | $17,000 | $16,000 | $33,000 |
| Total assets | $3.07M | $4.75M | $1.71M | $3.41M | $6.15M | $2.09M | $2.17M | $3.72M |
| Current liabilities | $2.09M | $2.06M | $2.78M | $2.43M | $3.31M | $3.64M | $3.23M | $2.32M |
| Total liabilities | $2.24M | $2.06M | $2.78M | $2.52M | $3.52M | $3.98M | $3.69M | $2.89M |
| Shareholders' equity | $835,000 | $2.70M | -$1.07M | $895,000 | $2.63M | -$1.89M | -$1.52M | $837,000 |
| Shares outstanding | 15.14M | 14.98M | 10.94M | 10.76M | 10.61M | 5.50M | 4.68M | 4.60M |
| Cash flow statement | ||||||||
| Operating cash flow | -$1.72M | -$1.74M | -$1.66M | -$2.50M | -$1.67M | -$1.65M | -$1.62M | -$2.57M |
| Capital expenditure | $1,000 | $0 | $3,000 | $6,000 | $0 | $1,000 | $0 | $1,000 |
| Free cash flow | -$1.72M | -$1.74M | -$1.66M | -$2.50M | -$1.67M | -$1.65M | -$1.62M | -$2.57M |
| Investing cash flow | -$1,000 | $0 | -$3,000 | -$6,000 | $0 | -$1,000 | $0 | -$1,000 |
| Financing cash flow | -$172,000 | $4.90M | $117,000 | -$288,000 | $5.98M | $1.68M | $196,000 | $15,000 |
| Depreciation & amortization | $2,000 | $3,000 | $3,000 | $3,000 | $4,000 | $5,000 | $12,000 | $15,000 |
| Stock-based compensation | $117,000 | $109,000 | $113,000 | $85,000 | $77,000 | $98,000 | $170,000 | $176,000 |
Free plan shows the latest 8 periods; Pro shows all 66 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.